Title : Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

Pub. Date : 2002 Sep

PMID : 12208222






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS AND RESULTS: Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) or placebo were administered intravenously for 6h to 504 patients in a randomised, placebo-controlled, double-blind study. Simendan CD59 molecule (CD59 blood group) Homo sapiens
2 CONCLUSION: s Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1) did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction. Simendan CD59 molecule (CD59 blood group) Homo sapiens